EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jeffrey Howard Lipton, Charles Chuah, Agnes Guerci-Bresler, Gianantonio Rosti, David Simpson, Stephanie Lustgarten, Nikolaus S. Trede, Victor M. Rivera, Tim Clackson, Frank G. Haluska, Michele Baccarani, Jorge E. Cortes, Francois Guilhot, Andreas Hochhaus, Timothy P. Hughes, Hagop M. Kantarjian, Neil P. Shah, Moshe Talpaz, Michael W.N. Deininger
Institutions: Princess Margaret Cancer Centre, Singapore General Hospital, Duke-NUS Medical School, Centre Hospitalier Régional et Universitaire de Nancy, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, North Shore Hospital, ARIAD Pharmaceuticals (United States), The University of Texas MD Anderson Cancer Center, Centre Hospitalier Universitaire de Poitiers, Jena University Hospital, South Australia Pathology, The University of Adelaide, University of California, San Francisco, University of Michigan, Huntsman Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2600930897